AU2001261674A1 - Treatment methods using 17906 and uses therefor - Google Patents
Treatment methods using 17906 and uses thereforInfo
- Publication number
- AU2001261674A1 AU2001261674A1 AU2001261674A AU6167401A AU2001261674A1 AU 2001261674 A1 AU2001261674 A1 AU 2001261674A1 AU 2001261674 A AU2001261674 A AU 2001261674A AU 6167401 A AU6167401 A AU 6167401A AU 2001261674 A1 AU2001261674 A1 AU 2001261674A1
- Authority
- AU
- Australia
- Prior art keywords
- differentiative
- cellular proliferative
- bone associated
- disease
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 4
- 210000000988 bone and bone Anatomy 0.000 abstract 7
- 230000001413 cellular effect Effects 0.000 abstract 7
- 201000010099 disease Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 230000002062 proliferating effect Effects 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000007435 diagnostic evaluation Methods 0.000 abstract 1
- 238000013154 diagnostic monitoring Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to methods and compositions for the diagnosis and treatment of bone associated or cellular proliferative or differentiative disease. Specifically, the present invention identifies 17906 genes which are differentially expressed in bone associated or cellular proliferative or differentiative disease states, relative to their expression in normal, or non-bone associated or non-cellular proliferative or differentiative disease states, and/or in response to manipulations relevant to bone associated or cellular proliferative or differentiative disease. The present invention describes methods for the diagnostic evaluation and prognosis of various bone associated or cellular proliferative or differentiative diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of bone associated or cellular proliferative or differentiative disease, and for monitoring the efficacy of compounds in clinical trials. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of bone associated or cellular proliferative or differentiative disease.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57168900A | 2000-05-16 | 2000-05-16 | |
| US09571689 | 2000-05-16 | ||
| PCT/US2001/015835 WO2001088157A2 (en) | 2000-05-16 | 2001-05-16 | Treatment methods using 17906 and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001261674A1 true AU2001261674A1 (en) | 2001-11-26 |
Family
ID=24284652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001261674A Abandoned AU2001261674A1 (en) | 2000-05-16 | 2001-05-16 | Treatment methods using 17906 and uses therefor |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020086302A1 (en) |
| EP (1) | EP1294902B1 (en) |
| AT (1) | ATE404677T1 (en) |
| AU (1) | AU2001261674A1 (en) |
| DE (1) | DE60135339D1 (en) |
| ES (1) | ES2310554T3 (en) |
| WO (1) | WO2001088157A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077001A1 (en) * | 2002-08-02 | 2004-04-22 | Millennium Pharmaceuticals Inc. | Use for carboxypeptidase-A4 in the diagnosis and treatment of metabolic disorders |
| WO2008012476A2 (en) * | 2006-07-26 | 2008-01-31 | L'oreal | Use of carboxypeptidases in the cosmetics and therapeutic field |
| FR2904223B1 (en) * | 2006-07-26 | 2013-01-11 | Oreal | USE OF CARBOXYPEPTIDASES IN THE COSMETIC AND THERAPEUTIC FIELD |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3472587B2 (en) * | 1992-08-28 | 2003-12-02 | アベンティス ファーマ株式会社 | Bone-related carboxypeptidase-like protein and method for producing the same |
| ES2122912B1 (en) * | 1996-09-20 | 2000-10-01 | Uviversitat Autonoma De Barcel | METALOCARBOXIPEPTIDASES AND MOLECULES DERIVED INHIBITORS AS ANTITUMORAL AGENTS. |
| US6309850B1 (en) * | 1997-04-10 | 2001-10-30 | Princeton University | Method of detecting procarboxypeptidase A and carboxypeptidase A levels in biological fluids |
| AU5340399A (en) * | 1998-08-10 | 2000-03-06 | Incyte Pharmaceuticals, Inc. | Proteases and associated proteins |
| AU2883700A (en) * | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
-
2001
- 2001-05-16 WO PCT/US2001/015835 patent/WO2001088157A2/en not_active Ceased
- 2001-05-16 AT AT01935595T patent/ATE404677T1/en not_active IP Right Cessation
- 2001-05-16 EP EP01935595A patent/EP1294902B1/en not_active Expired - Lifetime
- 2001-05-16 DE DE60135339T patent/DE60135339D1/en not_active Expired - Lifetime
- 2001-05-16 AU AU2001261674A patent/AU2001261674A1/en not_active Abandoned
- 2001-05-16 US US09/860,193 patent/US20020086302A1/en not_active Abandoned
- 2001-05-16 ES ES01935595T patent/ES2310554T3/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001088157A3 (en) | 2002-05-16 |
| US20020086302A1 (en) | 2002-07-04 |
| EP1294902B1 (en) | 2008-08-13 |
| ES2310554T3 (en) | 2009-01-16 |
| EP1294902A2 (en) | 2003-03-26 |
| WO2001088157A2 (en) | 2001-11-22 |
| ATE404677T1 (en) | 2008-08-15 |
| DE60135339D1 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004065576A3 (en) | Methods and compositions for the treatment of urological disorder using differential expressed polypeptides | |
| EP1403372A3 (en) | Composition and methods for the treatment and diagnosis of cardiovascular disease | |
| EP0904277A4 (en) | Compositions and methods for the treatment and diagnosis of cardiovascular disease | |
| WO2003065006A3 (en) | Methods and compositions for treating cancer | |
| WO2004092405A3 (en) | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof | |
| EP1100547A4 (en) | Compositions and methods for the treatment and diagnosis of cardiovascular disease | |
| WO2002032292A3 (en) | Methods for development and use of diagnostic and therapeutic agents | |
| WO2002059604A8 (en) | Diagnosis and treatment of multiple sclerosis | |
| ATE450622T1 (en) | GENES AND PROTEINS FOR PREVENTION, PREDICTION, PROGNOSIS AND THERAPY OF CARDIOVASCULAR DISEASE | |
| WO2001081634A3 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| WO2004063340A3 (en) | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4 | |
| AU2002350950A1 (en) | Compounds for imaging alzheimer's disease | |
| WO2003070883A3 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
| AU2001261674A1 (en) | Treatment methods using 17906 and uses therefor | |
| WO2006125830A3 (en) | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases | |
| WO2003073983A3 (en) | Methods and compositions in treating pain using diacylglycerol kinase epsilon | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| WO2003065871A3 (en) | Methods and compositions for treating hematological disorders | |
| AU2003224120A1 (en) | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases | |
| WO2003050504A3 (en) | Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 | |
| WO2003061573A3 (en) | Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo | |
| WO2004071411A3 (en) | Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 | |
| WO2004111270A3 (en) | Differential gene expression in schizophrenia | |
| WO2003053364A3 (en) | Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |